These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 10977427)

  • 21. Overview of the pharmacokinetics of fluvoxamine.
    van Harten J
    Clin Pharmacokinet; 1995; 29 Suppl 1():1-9. PubMed ID: 8846617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Cognitive Profile of Second-Generation Antidepressants in Elderly Nursing Home Residents With Depression.
    Bali V; Johnson ML; Chen H; Fleming ML; Holmes HM; Aparasu RR
    Ann Pharmacother; 2016 Feb; 50(2):96-105. PubMed ID: 26610873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response and discontinuation rates of newer antidepressants: a meta-analysis of randomized controlled trials in treating depression.
    Srisurapanont M
    J Med Assoc Thai; 1998 Jun; 81(6):387-92. PubMed ID: 9676069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Focus on paroxetine.
    Green B
    Curr Med Res Opin; 2003; 19(1):13-21. PubMed ID: 12661775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharma-Clinics. The drug of the month. Venlafaxine (Efexor)].
    Ansseau M
    Rev Med Liege; 1998 Feb; 53(2):106-8. PubMed ID: 9564231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD.
    Thorkelson G; Bielefeldt K; Szigethy E
    Inflamm Bowel Dis; 2016 Jun; 22(6):1509-22. PubMed ID: 27167571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinically significant drug interactions with newer antidepressants.
    Spina E; Trifirò G; Caraci F
    CNS Drugs; 2012 Jan; 26(1):39-67. PubMed ID: 22171584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluoxetine versus other types of pharmacotherapy for depression.
    Magni LR; Purgato M; Gastaldon C; Papola D; Furukawa TA; Cipriani A; Barbui C
    Cochrane Database Syst Rev; 2013 Jul; (7):CD004185. PubMed ID: 24353997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple serotonergic paths to antidepressant efficacy.
    Lutz PE
    J Neurophysiol; 2013 May; 109(9):2245-9. PubMed ID: 23343901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
    Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: risk for the foetus and the newborn].
    Favrelière S; Nourrisson A; Jaafari N; Pérault Pochat MC
    Encephale; 2010 Jun; 36 Suppl 2():D133-8. PubMed ID: 20513456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinically relevant drug interactions with new generation antidepressants and antipsychotics].
    Eckert A
    Ther Umsch; 2009 Jun; 66(6):485-92. PubMed ID: 19496045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. WITHDRAWN: Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs).
    Barbui C; Hotopf M; Freemantle N; Boynton J; Churchill R; Eccles MP; Geddes JR; Hardy R; Lewis G; Mason JM
    Cochrane Database Syst Rev; 2007 Jul; (3):CD002791. PubMed ID: 17636706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluoxetine versus other types of pharmacotherapy for depression.
    Cipriani A; Brambilla P; Furukawa T; Geddes J; Gregis M; Hotopf M; Malvini L; Barbui C
    Cochrane Database Syst Rev; 2005 Oct; (4):CD004185. PubMed ID: 16235353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review.
    Vaswani M; Linda FK; Ramesh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Feb; 27(1):85-102. PubMed ID: 12551730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.
    Hemeryck A; Belpaire FM
    Curr Drug Metab; 2002 Feb; 3(1):13-37. PubMed ID: 11876575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability].
    Gury C; Cousin F
    Encephale; 1999; 25(5):470-6. PubMed ID: 10598311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Escitalopram.
    Aronson S; Delgado P
    Drugs Today (Barc); 2004 Feb; 40(2):121-31. PubMed ID: 15045034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SSRIs in depression: a decade of progress.
    Goldstein BJ
    J Psychopharmacol; 1998; 12(3 Suppl B):S3. PubMed ID: 9808076
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug interactions of clinical significance with selective serotonin reuptake inhibitors.
    Mitchell PB
    Drug Saf; 1997 Dec; 17(6):390-406. PubMed ID: 9429838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.